(Q40675230)

22 September 2017

title

Severe parvovirus B19 infection in an immunocompetent child with hemophilia A (English)

1 reference

22 September 2017

0 references

0 references

Coumau E

1

1 reference

22 September 2017

Peynet J

2

1 reference

22 September 2017

Harzic M

3

1 reference

22 September 2017

Béal G

4

1 reference

22 September 2017

Castaigne S

5

1 reference

22 September 2017

Leverger G

6

1 reference

22 September 2017

Foucaud P

7

1 reference

22 September 2017

publication date

1 January 1996

1 reference

22 September 2017

published in

Archives de Pediatrie

1 reference

22 September 2017

volume

3

1 reference

22 September 2017

issue

1

1 reference

22 September 2017

page(s)

35-39

1 reference

B19 parvovirus DNA in solvent/detergent-treated anti-haemophilia concentrates

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2896%2980006-6

7 January 2021

Encephalitis associated with erythema infectiosum.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2896%2980006-6

7 January 2021

Neuralgic amyotrophy due to parvovirus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2896%2980006-6

7 January 2021

Effects of tamoxifen on uterus

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2896%2980006-6

7 January 2021

Persistent human parvovirus B19 infection following an acute infection with meningitis in an immunocompetent patient

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2896%2980006-6

7 January 2021

Experimental parvoviral infection in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2896%2980006-6

7 January 2021

Variation of erythroid and myeloid precursors in the marrow and peripheral blood of volunteer subjects infected with human parvovirus (B19).

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2896%2980006-6

7 January 2021

Chronic neutropenia of childhood: frequent association with parvovirus infection and correlations with bone marrow culture studies

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2896%2980006-6

7 January 2021

Parvovirus B19-associated hemophagocytic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2896%2980006-6

7 January 2021

Viral-associated haemophagocytosis with parvovirus-B19-related pancytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2896%2980006-6

7 January 2021

Life-threatening human parvovirus B19 infection in immunocompetent haemophilia

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2896%2980006-6

7 January 2021

Parvovirus B19 for the hematologist

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2896%2980006-6

7 January 2021

Human parvovirus infection in haemophiliacs first infused with treated clotting factor concentrates

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2896%2980006-6

7 January 2021

Should measures be taken to reduce the risk of human parvovirus (B19) infection by transfusion of blood components and clotting factor concentrates?

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2896%2980006-6

7 January 2021

Symptomatic parvovirus B19 infection and heat-treated factor IX concentrate

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2896%2980006-6

7 January 2021

Hypoplastic anemia in a hemophiliac first infused with a solvent/detergent treated factor VIII concentrate: the role of human B19 parvovirus

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2896%2980006-6

7 January 2021

Severe heat treatment of freeze-dried coagulation factor concentrates: is hotter necessarily better?

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2896%2980006-6

7 January 2021

Nanofiltration, a new specific virus elimination method applied to high-purity factor IX and factor XI concentrates

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2896%2980006-6

7 January 2021

Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2896%2980006-6

7 January 2021

Viral contamination of blood products

1 reference

https://api.crossref.org/works/10.1016%2FS0929-693X%2896%2980006-6

7 January 2021

10.1016/S0929-693X(96)80006-6

Identifiers

DOI

1 reference

22 September 2017

1 reference